Dr Daniel Ford is a consultant clinical oncologist based in Birmingham, practising privately at The Harborne Hospital as part of HCA Healthcare UK. He uses he/him pronouns and has extensive experience in the diagnosis, treatment and management of urological cancers, including prostate, bladder and kidney cancer.

He qualified in medicine with honours and subsequently gained postgraduate qualifications including MB ChB (hons), BSc, MRCP and FRCR. He brings more than two decades of clinical experience and works across both NHS and private settings, providing advanced oncological care.

Dr Ford’s areas of expertise include a comprehensive range of oncological treatments for prostate, kidney and bladder cancers. His clinical practice encompasses hormonal therapies, chemotherapy, immunotherapy, conventional radiotherapy and modern techniques such as stereotactic ablative radiotherapy (SABR), MRIdian MR-linac guided radiotherapy and prostate brachytherapy. He also leads and assesses clinical trial activity, contributing to research that informs new treatment protocols and optimises patient outcomes.

He is actively involved in cancer research and regional clinical leadership, serving as deputy clinical cancer lead for the West Midlands NIHR Clinical Research Network. In this role he supports and promotes research across the region, and leads local trials exploring advanced fractionation techniques and radiotherapy applications in prostate cancer.

Committed to patient-centred care, Dr Ford focuses on clear communication, shared decision-making and tailored treatment planning to support patients and their families throughout the course of care. His clinical interests extend to trial participation and precision radiotherapy techniques, reflecting a dedication to both evidence-based practice and innovation in clinical oncology.

His qualifications and professional memberships underpin his clinical expertise, and he continues to contribute to the advancement of oncological treatments through both clinical service and research engagement.